Bcl-X L, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis

Cancer Letters

Volumn 318, Issue 1, 2012, Pages 53-60

  Yeo, Alan T ^a   Porco, John A ^a,b   Gilmore, Thomas D ^a,b  

^a USA   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Apoptosis; B cell lymphoma; Bcl 2; Bcl X L; NF B; Parthenolide

Indexed keywords

CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARTHENOLIDE; PROTEIN BCL 2; PROTEIN BCL XL; TRANSCRIPTION FACTOR REL; DNA; DNA BINDING PROTEIN; HIVEN86A PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEAR PROTEIN; PROTEIN BCL X; SESQUITERPENE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; DRUG ANTAGONISM; GEL MOBILITY SHIFT ASSAY; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELL PROLIFERATION; DNA, NEOPLASM; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; LYMPHOMA, B-CELL; NF-KAPPA B; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SESQUITERPENES; TUMOR CELLS, CULTURED;

EID: 84857141696     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.035     Document Type: Article

References (41)

1. Courtois G., Gilmore T.D. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene 2006, 25:6831-6843.
2. Gilmore T.D., Kalaitzidis D., Liang M.-C., Starczynowski D.T. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene 2004, 23:2275-2286.
3. Gilmore T.D., Cormier C., Jean-Jacques J., Gapuzan M.-E. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene 2001, 20:7098-7103.
4. Chin M., Herscovitch M., Zhang N., Waxman D.J., Gilmore T.D. Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile. Oncogene 2009, 28:2100-2111.
5. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson J., Lu L., Lewis D.B., Tibshirani G., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.E., Armitage J.O., Warnke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
6. Iqbal J., Neppalli V.T., Wright G., Dave B.J., Horsman D.E., Rosenwald A., Lynch J., Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Campo E., Ott G., Müller-Hermelink H.K., Delabie J., Jaffe E.S., Grogan T.M., Connors J.M., Vose J.M., Armitage J.O., Staudt L.M., Chan W.C. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J. Clin. Oncol. 2006, 24:961-968.
7. Zhou F., Yang Y., Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J. 2011, 278:403-413.
8. Pajak B., Gajkowska B., Orzechowski A. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem. Cytobiol. 2008, 46:129-135.
9. Ghantous, Gali-Muhtasib H., Vuorela H., Saliba N.A., Darwiche N. What made sesquiterpene lactones reach cancer clinical trials?. Drug Discov. Today. 2010, 15:668-678.
10. García-Piñeres A.J., Castro V., Mora G., Schmidt T.J., Strunck E., Pahl H.L., Merfort I. Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 2001, 276:39713-39720.
11. Kwok B.H., Koh B., Ndubuisi M.I., Elofsson M., Crews C.M. The anti-inflammatory natural product parthenolide from the medical herb Feverfew directly binds to and inhibits IκB kinase. J. Chem. Biol. 2001, 8:759-766.
12. Kollmann K., Heller G., Ott R.G., Scheicher R., Zebedin-Brandl E., Schneckenleithner C., Simma O., Warsch W., Eckelhart E., Hoeblbl A., Bilban M., Zöchbauer-Müller S., Malubres M., Sexl V. c-Jun promotes BCR-ABL lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6. Blood 2011, 117:4065-4075.
13. Liang M.-C., Bardhan S., Porco J.A., Gilmore T.D. The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IκBα-deficient diffuse large B-cell lymphoma cell line. Cancer Lett. 2006, 241:69-78.
14. Liang M.-C., Bardhan S., Pace E.A., Rosman D., Beutler J.A., Porco J.A., Gilmore T.D. Inhibition of transcription factor NF-κB signaling proteins IKKβ and p65 through specific cysteine residues by epoxyquinone A monomer: correlation with its anti-cancer cell growth activity. Biochem. Pharmacol. 2006, 71:634-645.
15. Kalaitzidis D., Davis R.E., Rosenwald A., Staudt L.M., Gilmore T.D. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-κB signal transduction pathway. Oncogene 2002, 21:8759-8768.
16. Vaughn C.P., Crockett D.K., Lin Z., Lim M.S., Elenitoba-Johnson K.S. Identification of proteins released by follicular lymphoma-derived cells using a mass spectrometry-based approach. Proteomics 2006, 6:3223-3230.
17. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001, 194:1861-1874.
18. Menezes J., Leibold W., Klein G., Clements G. Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional EBV-genome-negative African Burkitt's lymphoma. Biomedicine 1975, 22:276-284.
19. Ngo V.N., Davis R.E., Lamy L., Yu X., Zhao H., Lenz G., Lam L.T., Dave S., Yang L., Powell J., Staudt L.M. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006, 441:106-110.
20. Contreras-Salazar B., Ehlin-Henriksson B., Klein G., Masucci M.G. Up-regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. J. Virol. 1990, 64:5441-5447.
21. Carter K.L., Cahir-McFarland E., Kieff E. Epstein-Barr virus-induced changes in B-lymphocyte gene expression. J. Virol. 2002, 76:10427-10436.
22. Gilmore T.D., Jean-Jacques J., Richards R., Cormier C., Kim J., Kalaitzidis D. Stable expression of the avian retroviral oncoprotein v-Rel in avian, mouse, and dog cell lines. Virology 2003, 316:9-16.
23. Wagner S., Hofmann A., Siedle B., Terfloth L., Merfort I. Development of a structural model for NF-kB inhibition of sequiterpene lactones using self-organizing neural networks. J. Med. Chem. 2006, 49:2241-2252.
24. Tsujimoto Y., Finger L.R., Yunis J., Nowell P.C., Croce C.M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984, 226:1097-1099.
25. Cabannes E., Khan G., Aillet F., Jarrett R.F., Hay R.T. Mutations in the IκBα gene in Hodgkin's disease suggest a tumour suppressor role for IκBα. Oncogene 1999, 18:3063-3070.
26. L. Mol. Cell. Biol. 2000, 20:2687-2695.
27. Bargou R.C., Leng C., Krappmann D., Emmerich F., Mapara M.Y., Bommert K., Royer H.D., Scheidereit C., Dörken B. High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996, 87:4340-4347.
28. Gerondakis S., Grumont R., Gugasyan R., Wong L., Isomura I., Ho W., Banerjee A. Unravelling the complexities of the NF-κB signaling pathway using mouse knockout and transgenic models. Oncogene 2006, 25:6781-6799.
29. Hayashi S., Sakurai H., Hayashi A., Tanaka Y., Hatashita M., Shioura H. Inhibition of NF-κB by combination therapy with parthenolide and hyperthermia and kinetics of apoptosis induction and cell cycle arrest in human lung adenocarcinoma cells. Int. J. Mol. Med. 2010, 25:81-87.
30. Zhang S., Lin Z.N., Yang C.F., Shi X., Ong C.N., Shen H.M. Suppressed NF-κB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-α-induced apoptosis in human cancer cells. Carcinogenesis 2004, 25:2191-2199.
31. Zunino S.J., Ducore J.M., Storms D.H. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Lett. 2007, 254:119-127.
32. Youle R., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
33. Luo D., Cheng S.C., Xie H., Xie Y. Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line. Biochem. Cell Biol. 2000, 78:119-126.
34. Simonian P.L., Grillot D.A., Nuñez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997, 90:1208-1216.
35. L rescues Ramos B cells from Fas-mediated apoptosis. Eur. J. Immunol. 1997, 27:3485-3491.
36. L, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19:1294-1305.
37. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., Huang D.C.S. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 2005, 17:393-403.
38. Certo M., Moore V.D.G., Nishino M., Wei G., Korsemeyer S., Armstrong S.A., Letai A. Mitochondria primed by death signals determine cellular addiction to anti-apoptotic BCL-2 family members. Cancer Cell 2006, 9:351-365.
39. Faber A.C., Corcoran R.B., Ebi H., Sequist L.V., Waltman B.A., Chung E., Incio J., Digumarthy S.R., Pollack S.F., Song Y., Muzikansky A., Lifshits E., Roberge S., Coffman E.J., Benes C.H., Gómez H.L., Baselga J., Arteaga C.L., Rivera M.N., Dias-Santagata D., Jain R.K., Engelman J.A. BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors. Cancer Discovery 2011, 1:352-365.
40. Guzman M.L., Rossi R.M., Neelakantan S., Li X., Corbett C.A., Hassane D.C., Becker M.W., Bennett J.M., Sullivan E., Lachowicz J.L., Vaughan A., Sweeney C.J., Matthews W., Carroll M., Liesveld J.L., Crooks P.A., Jordan C.T. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007, 110:4427-4435.
41. Skalska J., Brooks P.S., Nadtochiy S.M., Hilchey S.P., Jordan C.T., Guzman M.L., Maggirwar S.B., Briehl M.M., Bernstein S.H. Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. PLoS One 2009, 4:e8115.